CHDI 00580985

Key Product Details

Product Description

CHDI 00580985 is a potent and selective ROCK inhibitor (IC₅₀ values are 3 nM and 8 nM in biochemical (ROCK2) and cellular assays respectively). CHDI 00580985 inhibits ROCK-mediated substrate (MYPT1) phosphorylation (IC₅₀ = 4 nM). In vivo, CHDI 00580985 reduces ROCK signaling in Huntington's disease mouse models in pharmacodynamic assay. CHDI 00580985 is bioavailable and brain penetrant.

Licensing Information

Sold under license from CHDI Foundation

Product Specifications for CHDI 00580985

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CHDI 00580985

The following data is based on the product molecular weight 372.44.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.68 mL	13.42 mL	26.85 mL
5 mM	0.54 mL	2.68 mL	5.37 mL
10 mM	0.27 mL	1.34 mL	2.68 mL
50 mM	0.05 mL	0.27 mL	0.54 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Ladduwahetty Identification of a potent, selective, and brain-penetrant Rho kinase inhibitor and its activity in a mouse model of Huntington's disease. J.Med.Chem. 2022 PMID: 35816678

Product Documents for CHDI 00580985